205 related articles for article (PubMed ID: 23278399)
1. Entry inhibitors directed towards glycoprotein gp120: an overview on a promising target for HIV-1 therapy.
Flores A; Quesada E
Curr Med Chem; 2013 Feb; 20(6):751-71. PubMed ID: 23278399
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of HIV-1 entry: multiple keys to close the door.
Hertje M; Zhou M; Dietrich U
ChemMedChem; 2010 Nov; 5(11):1825-35. PubMed ID: 20845361
[No Abstract] [Full Text] [Related]
3. A broad spectrum anti-HIV inhibitor significantly disturbs V1/V2 domain rearrangements of HIV-1 gp120 and inhibits virus entry.
Berinyuy E; Soliman ME
J Recept Signal Transduct Res; 2016; 36(2):119-29. PubMed ID: 26446906
[TBL] [Abstract][Full Text] [Related]
4. Development of Small-molecule HIV Entry Inhibitors Specifically Targeting gp120 or gp41.
Lu L; Yu F; Cai L; Debnath AK; Jiang S
Curr Top Med Chem; 2016; 16(10):1074-90. PubMed ID: 26324044
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, antiviral activity and resistance of a novel small molecule HIV-1 entry inhibitor.
Curreli F; Haque K; Xie L; Qiu Q; Xu J; Yong W; Tong X; Debnath AK
Bioorg Med Chem; 2015 Dec; 23(24):7618-28. PubMed ID: 26602829
[TBL] [Abstract][Full Text] [Related]
6. The Discovery and Development of Oxalamide and Pyrrole Small Molecule Inhibitors of gp120 and HIV Entry - A Review.
Motati DR; Uredi D; Watkins EB
Curr Top Med Chem; 2019; 19(18):1650-1675. PubMed ID: 31424369
[TBL] [Abstract][Full Text] [Related]
7. Viral surface glycoproteins, gp120 and gp41, as potential drug targets against HIV-1: brief overview one quarter of a century past the approval of zidovudine, the first anti-retroviral drug.
Teixeira C; Gomes JR; Gomes P; Maurel F; Barbault F
Eur J Med Chem; 2011 Apr; 46(4):979-92. PubMed ID: 21345545
[TBL] [Abstract][Full Text] [Related]
8. Computational design, synthesis and evaluation of new sulphonamide derivatives targeting HIV-1 gp120.
Vangala R; Sivan SK; Peddi SR; Manga V
J Comput Aided Mol Des; 2020 Jan; 34(1):39-54. PubMed ID: 31792886
[TBL] [Abstract][Full Text] [Related]
9. Naturally occurring variability in the envelope glycoprotein of HIV-1 and development of cell entry inhibitors.
Brower ET; Schön A; Freire E
Biochemistry; 2010 Mar; 49(11):2359-67. PubMed ID: 20166763
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, Antiviral Potency, in Vitro ADMET, and X-ray Structure of Potent CD4 Mimics as Entry Inhibitors That Target the Phe43 Cavity of HIV-1 gp120.
Curreli F; Kwon YD; Belov DS; Ramesh RR; Kurkin AV; Altieri A; Kwong PD; Debnath AK
J Med Chem; 2017 Apr; 60(7):3124-3153. PubMed ID: 28266845
[TBL] [Abstract][Full Text] [Related]
11. In Silico Identification of Novel Aromatic Compounds as Potential HIV-1 Entry Inhibitors Mimicking Cellular Receptor CD4.
Andrianov AM; Nikolaev GI; Kornoushenko YV; Xu W; Jiang S; Tuzikov AV
Viruses; 2019 Aug; 11(8):. PubMed ID: 31412617
[TBL] [Abstract][Full Text] [Related]
12. HIV-1 gp120 as a therapeutic target: navigating a moving labyrinth.
Acharya P; Lusvarghi S; Bewley CA; Kwong PD
Expert Opin Ther Targets; 2015 Jun; 19(6):765-83. PubMed ID: 25724219
[TBL] [Abstract][Full Text] [Related]
13. Multivalent benzoboroxole functionalized polymers as gp120 glycan targeted microbicide entry inhibitors.
Jay JI; Lai BE; Myszka DG; Mahalingam A; Langheinrich K; Katz DF; Kiser PF
Mol Pharm; 2010 Feb; 7(1):116-29. PubMed ID: 20014858
[TBL] [Abstract][Full Text] [Related]
14. Peptide triazole inactivators of HIV-1: how do they work and what is their potential?
Chaiken I; Rashad AA
Future Med Chem; 2015; 7(17):2305-10. PubMed ID: 26599515
[No Abstract] [Full Text] [Related]
15. Computational studies identifying entry inhibitor scaffolds targeting the Phe43 cavity of HIV-1 gp120.
Tintori C; Selvaraj M; Badia R; Clotet B; Esté JA; Botta M
ChemMedChem; 2013 Mar; 8(3):475-83. PubMed ID: 23404750
[TBL] [Abstract][Full Text] [Related]
16. Anionic Carbosilane Dendrimers Destabilize the GP120-CD4 Complex Blocking HIV-1 Entry and Cell to Cell Fusion.
Guerrero-Beltran C; Rodriguez-Izquierdo I; Serramia MJ; Araya-Durán I; Márquez-Miranda V; Gomez R; de la Mata FJ; Leal M; González-Nilo F; Muñoz-Fernández MA
Bioconjug Chem; 2018 May; 29(5):1584-1594. PubMed ID: 29570280
[TBL] [Abstract][Full Text] [Related]
17. Targeting protein-protein interactions: a promising avenue of anti-HIV drug discovery.
Zhan P; Li W; Chen H; Liu X
Curr Med Chem; 2010; 17(29):3393-409. PubMed ID: 20712566
[TBL] [Abstract][Full Text] [Related]
18. A peptidomimetic HIV-entry inhibitor directed against the CD4 binding site of the viral glycoprotein gp120.
Neffe AT; Meyer B
Angew Chem Int Ed Engl; 2004 May; 43(22):2937-40. PubMed ID: 15170309
[No Abstract] [Full Text] [Related]
19. Feglymycin, a unique natural bacterial antibiotic peptide, inhibits HIV entry by targeting the viral envelope protein gp120.
Férir G; Hänchen A; François KO; Hoorelbeke B; Huskens D; Dettner F; Süssmuth RD; Schols D
Virology; 2012 Nov; 433(2):308-19. PubMed ID: 22959895
[TBL] [Abstract][Full Text] [Related]
20. The Cellular Thioredoxin-1/Thioredoxin Reductase-1 Driven Oxidoreduction Represents a Chemotherapeutic Target for HIV-1 Entry Inhibition.
Reiser K; Mathys L; Curbo S; Pannecouque C; Noppen S; Liekens S; Engman L; Lundberg M; Balzarini J; Karlsson A
PLoS One; 2016; 11(1):e0147773. PubMed ID: 26816344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
